ScreenerHero
CTXCaptor Therapeutics Spolka Akcyjna
GPW · PL · Healthcare · Biotechnology · captortherapeutics.com
73.20PLN0.00%Mkt Cap: 117.41M $P/E: —

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that …

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap117.41M $
Enterprise Value114.06M $
Revenue (TTM)603.27K $
Gross Profit814.23K $
Net Income (TTM)-10.64M $
Revenue/Share0.1092 USD
Last Price73.20 PLN
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees82
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLCPTRT00014
Valuation
P/E (Trailing)—
P/E (Forward)-273.85
PEG—
EV/EBITDA-11.22
EV/Revenue189.07
P/S189.31
P/B32.80
EPS (TTM)-7.76
EPS (Forward)—
52W Range
33.0072% of range89.20
52W High89.20 PLN
52W Low33.00 PLN
Profitability
Gross Margin68.99%
Oper. Margin-3433.54%
EBITDA Margin0.00%
Profit Margin-901.22%
ROE-178.86%
ROA-104.93%
Growth
Revenue Growth-87.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.45M $
CapEx (TTM)53.18K $
FCF Margin-1114.70%
FCF Yield-5.73%
Net Debt-3.72M $
Net Debt/EBITDA0.37
Balance Sheet
Debt/Equity0.15
Current Ratio1.60
Quick Ratio1.60
Book Value/Sh2.171 PLN
Cash/Share2.815 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 PLN
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)86.83 PLN
Upside (mean)+18.6%
Target Range67.00 PLN – 110.00 PLN
PLN67.00+18.6% to meanPLN110.00
# Analysts3
Ownership
Shares Out.6.33M
Float4.47M
Insiders29.31%
Institutions29.65%
Technical
SMA 5074.64 (-1.9%)
SMA 20074.61 (-1.9%)
Beta0.55
S&P 52W Chg18.16%
Avg Vol (30d)3.42K
Avg Vol (10d)5.29K
Technical Indicators
RSI (14)50.7
MACD-0.7789
MACD Signal-0.9959
MACD Hist.+0.2169
BB Upper76.58 PLN
BB Middle72.61 PLN
BB Lower68.64 PLN
BB Width10.94%
ATR (14)2.657 PLN
Vol Ratio (20d)1.08x